We help our customers conduct cost-efficient observational studies worldwide
Along with clinical specialists, our team of epidemiologists, statisticians, clinicians, health economists and qualitative researchers conduct effective field, secondary data and hybrid observational studies to achieve our client’s goals.
OXON offers proven experience and a large portfolio of completed studies in a broad range of therapeutic areas and high-profile publications, including original articles appearing in The Lancet.
Our staff have worked on studies in Obesity, High blood pressure, Lipids, Anti-coagulants, Anti-thrombotic and Heart failure, having completed studies with cardiovascular and Stroke safety endpoints. Several of these projects have led to full publications in The Lancet, with OXON authors.
Stuart Pocock, Professor of Medical Statistics, London School of Hygiene & Tropical Medicine, who is an international leader in cardiovascular trials and registries and evaluation of Cardiovascular safety issues, consults us in this field.
OXON has worked on studies in Alzheimer’s disease and other dementias, Parkinson’s disease, Multiple sclerosis, Epilepsy, Schizophrenia, Anti-Psychotics, Anti-depressants, with one publication in The Lancet, among others.
One of our senior clinical epidemiologists is chief author of the international textbook: ´Evidence-based Dementia Practice´, Published by Wiley-Blackwells, Oxford and was Founding Editor of the Cochrane Dementia Group.
OXON has worked on a wide range of rare diseases such as studies in Fabry, Gaucher, Pompe, and Spinal Muscular Atrophy. These studies include many different approaches, with emphasis on the use of ultra-rare orphan disease registries.
We have worked on studies in Rheumatoid Arthritis, Atopic Dermatitis, Psoriasis, Organ Transplant Rejection, and other medical conditions from an immunologic point of view. We have recently successfully finalised a PAS Evaluation study in Transplant Rejection.
We have experience in studies in Keratoconjunctivitis.
OXON has developed a novel approach to studying drug exposure during pregnancy, with a follow up on pregnancy, birth, infant and childhood outcomes with the use of prospective pregnancy registries and hybrid database approaches.